Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 versus docetaxel + carboplatin + trastuzumab + pertuzumab as neoadjuvant therapy for previously untreated HER2-positive early or locally advanced breast cancer
CTR20254129Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab rezetecan in breast cancer (2 arms), sponsored by Suzhou Shengdiya Biopharmaceuticals. Primary endpoint: Total pathologic complete response assessed by independent review committee. Started Oct 2025; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254129.